1月26日，诺诚健华跌2.02%，成交额1.86亿元。两融数据显示，当日诺诚健华获融资买入额1573.40万 元，融资偿还1308.88万元，融资净买入264.52万元。截至1月26日，诺诚健华融资融券余额合计4.09亿 元。 融资方面，诺诚健华当日融资买入1573.40万元。当前融资余额4.08亿元，占流通市值的7.66%，融资余 额超过近一年90%分位水平，处于高位。 截至9月30日，诺诚健华股东户数1.65万，较上期增加8.66%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，诺诚健华实现营业收入11.15亿元，同比增长59.85%；归母净利润-6441.49万元，同比增长 76.61%。 机构持仓方面，截止2025年9月30日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第六大流通股东，持股1215.49万股，相比上期减少42.71万股。万家优选（161903）位 居第七大流通股东，持股1000.00万股，为新进股东。平安医疗健康混合A（003032）位居第八大流通股 东，持股862.66万股，为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东 ...

【环球网财经综合报道】随着2025年基金四季报的密集披露，公募基金的持仓路径图全景式展现在投资者面前。数据 宝最新统计显示，截至去年四季度末，共有2977只股票现身基金重仓股名单。从机构控盘程度来看，基金调仓换股的 动向颇为明显，其中共有107只个股的基金持股比例超过10%，显示出机构资金对这些个股具有极高的话语权和控盘 力。 机构抱团现象在基金高比例持仓股中依然显著。一般而言，基金控盘比例高的个股往往伴随着多家基金扎堆持有。数 据显示，这107只个股中，有100家以上基金扎堆持有的多达42只，50至99家基金集体持有的有29只。值得注意的是， 宁德时代虽然持股比例为11.63%，但持有基金家数最多，高达2056家基金抱团持有。中际旭创、紫金矿业、新易盛的 持有基金家数也均超过1300家，分别达到1809家、1800家和1396家。 从板块分布来看，基金高比例持仓的个股呈现出明显的"硬科技"与"创新"特征。107只个股中，科创板有42只，创业板 有27只，沪深主板有31只，北交所有7只。行业分布上，电子、医药生物、电力设备三大行业成为机构最青睐的领 域，分别有28只、20只、11只个股上榜。这表明在当前的宏观 ...

| 序号 | 股票代码 | 股票名称 | 数量(股) | 公允价值(元) | 占基金资产净值比 | | --- | --- | --- | --- | --- | --- | | 1 | 300308 | 中际旭创 | 2.035.762 | 1,241,814,820.00 | | | ଧ | 01801 | 信达生物 | 13, 610, 794 | 937, 382, 528. 45 | | | 3 | 600160 | 巨化股份 | 22, 584, 497 | 867, 696, 374. 74 | | | র্ব | 300750 | 宁德时代 | 2, 330, 228 | 855, 799, 535. 28 | | | 5 | 688099 | 晶晨股份 | 8.519.889 | 743. 189. 917. 47 | | | 6 | 688525 | 佰维存储 | 5,872,779 | 674. 136. 301. 41 | | | 7 | 09969 | 诺诚健华 | 50. 789. 000 | 564. 245. 779. 13 | | | 8 | 01860 | 汇量科技 | 3 ...

Group 1 - The core point of the article is that as of January 9, 2026, the number of A-share shareholders for the company is approximately 19,300 [1]

Group 1 - The core viewpoint of the news is that Nocera Biopharma has seen a continuous increase in its stock price, reflecting positive market sentiment and potential investment opportunities [1] - As of January 12, Nocera Biopharma's stock price is 22.58 yuan per share, with a total market capitalization of 39.846 billion yuan and a trading volume of 2.12 billion yuan [1] - The company specializes in the research, production, and commercialization of biopharmaceuticals, focusing on unmet clinical needs in oncology and autoimmune diseases [1] Group 2 - Morgan Stanley's fund holds a significant position in Nocera Biopharma, with the Morgan Stanley Hong Kong-Shanghai Select Mixed A Fund owning 420,000 shares, representing 6.87% of the fund's net value [2] - The fund has generated a floating profit of approximately 69,720 yuan during the four-day stock price increase [2] - The Morgan Stanley Hong Kong-Shanghai Select Mixed A Fund has a total asset size of 67.3812 million yuan and has achieved a year-to-date return of 14.11% [2]

Core Viewpoint - The approval and clinical application of the new generation TRK inhibitor, Zolacotrine (Yinoxin, ICP-723), marks a significant breakthrough in China's broad-spectrum anti-cancer drug development, providing better treatment options for patients with NTRK fusion-positive solid tumors [1][3]. Group 1: Drug Development and Approval - Zolacotrine is the first domestically developed TRK inhibitor approved for clinical use in China, with prescriptions already issued in multiple hospitals [1][3]. - The drug addresses unmet clinical needs for patients with NTRK fusion-positive tumors, which are prevalent in over 26 types of solid tumors [4]. Group 2: Clinical Efficacy - Clinical studies show Zolacotrine has a total response rate (ORR) of 89.1%, with a disease control rate (DCR) of 96.4%, and a 24-month progression-free survival rate (PFS) of 77.4% [5]. - The drug demonstrates a total survival rate (OS) of 90.8%, indicating its potential to provide long-term relief for patients [5]. Group 3: Safety and Administration - Zolacotrine has a low rate of treatment-related adverse events leading to permanent discontinuation, at only 0.4%, enhancing patient compliance [7]. - The once-daily oral administration of Zolacotrine offers convenience for long-term treatment [7]. Group 4: Overcoming Resistance - Zolacotrine effectively overcomes resistance issues associated with first-generation TRK inhibitors, maintaining strong inhibitory activity against common mutations in the TRK kinase domain [9]. Group 5: CNS Penetration - The drug's unique molecular structure allows it to effectively penetrate the blood-brain barrier, achieving a 100% objective response rate in intracranial lesions, thus providing comprehensive protection for patients with brain metastases [10]. Group 6: Company Perspective - The CEO of the company expressed gratitude towards regulatory bodies, clinical experts, and partners for their support in the development and launch of Zolacotrine, emphasizing its role in improving the quality of life for cancer patients [12].

Core Insights - The biopharmaceutical industry is at a significant historical juncture in 2025, marking the end of the "14th Five-Year Plan" and the beginning of the "15th Five-Year Plan," with a focus on balancing technological innovation and commercial rationality, as well as global and local strategies [1][6] - The company, Innovent Biologics, celebrates its 10th anniversary in 2025, achieving significant milestones including a record-breaking collaboration worth over $2 billion with Zenas and achieving profitability two years ahead of schedule [1][6] Company Achievements - Innovent Biologics has successfully launched two innovative drugs, including the first approved CD19 monoclonal antibody for diffuse large B-cell lymphoma (DLBCL) and the first domestically developed TRK inhibitor [7] - The company's core product, Obinutuzumab, has received approval for first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and has been included in the national medical insurance, benefiting more patients [7] Research and Development Progress - The company has made breakthroughs in innovative drug development, with the first BCL2 inhibitor recognized as a breakthrough therapy in China, and multiple clinical trials for various indications are accelerating [8] - The company is advancing its ADC platform with the first ADC drug entering clinical stages, enhancing its competitiveness in solid tumors [8] Future Strategy - Innovent Biologics aims to leverage "Chinese originality" and "global vision" to embark on a new decade of growth, with plans to launch five to six innovative drugs and accelerate globalization efforts [9] - The company is committed to maintaining an entrepreneurial spirit and enhancing its overseas team capabilities to achieve global commercialization of three to four products [9]

Group 1 - The stock price of Nocera Biopharma (688428) closed at 21.65 yuan on January 7, 2026, with an increase of 3.49% and a turnover rate of 3.57% [1] - The trading volume was 95,800 shares, with a total transaction amount of 206 million yuan [1] - On January 7, the net outflow of funds from major investors was 1.24 million yuan, while retail investors saw a net inflow of 1.70 million yuan [2] Group 2 - As of December 31, 2025, the total share capital of Nocera Biopharma remains unchanged at 25 billion ordinary shares, with no change in the number of issued shares [2] - The number of shares listed on the Hong Kong Stock Exchange is 1,496,284,235, which includes 1,493,798,235 issued shares and 2,486,000 treasury shares [1][2] - The number of shares listed on the Sci-Tech Innovation Board is 268,359,717 [1][2] - The company has two equity incentive plans, with 4,531,250 shares remaining to be granted under the 2023 RMB stock incentive plan and 9,645,200 shares under the 2024 RMB stock incentive plan [1]

Core Viewpoint - As of December 31, 2025, the number of A-share shareholders for the company is expected to be approximately 18,100 [1] Summary by Relevant Categories Company Information - The company, 诺诚健华, has indicated that it anticipates having around 18,100 A-share shareholders by the end of 2025 [1]

Group 1 - The company, Nocera, stated that its pipeline advancement and commercialization expansion are progressing smoothly according to plans and targets, with normal operations [1] - The company's stock price in the secondary market is influenced by various factors, and investors are advised to be cautious about investment risks [1] - The company will decide whether to initiate a buyback based on its development status and the capital market environment [1]